STORY HIGHLIGHTS <\/p>\n
(CNN) -- A highly anticipated test of an experimental Ebola vaccine will begin this week at the National Institutes of Health, amid mounting anxiety about the spread of the deadly virus in West Africa. <\/p>\n
After an expedited review by the U.S. Food and Drug Administration, researchers were given the green light to begin what's called a human safety trial, said Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID). <\/p>\n
It will be the first test of this type of Ebola vaccine in humans. <\/p>\n
The experimental vaccine, developed by the pharmaceutical company GlaxoSmithKline and the NIAID, will first be given to three healthy human volunteers to see if they suffer any adverse effects. If deemed safe, it will then be given to another small group of volunteers, aged 18 to 50, to see if it produces a strong immune response to the virus. All will be monitored closely for side effects. <\/p>\n
Ebola outbreak in Africa <\/p>\n
Ebola outbreak in Africa <\/p>\n
Ebola outbreak in Africa <\/p>\n
Ebola outbreak in Africa <\/p>\n
Ebola outbreak in Africa <\/p>\n
<\/p>\n
Read the rest here:<\/p>\n
Human trial of Ebola vaccine begins<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" STORY HIGHLIGHTS (CNN) -- A highly anticipated test of an experimental Ebola vaccine will begin this week at the National Institutes of Health, amid mounting anxiety about the spread of the deadly virus in West Africa. Continue reading